Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease

Neurology

Volumn 67, Issue 6, 2006, Pages 998-1005

  Zhu, C W ^a,b   Scarmeas, N ^c,d   Torgan, R ^c,d   Albert, M ^e   Brandt, J ^e   Blacker, D ^f   Sano, M ^a,b   Stern, Y ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF LIVING; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PATIENT CARE; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; SOCIAL ASPECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; COST OF ILLNESS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PATIENT CARE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES;

EID: 33748995923     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000230160.13272.1b     Document Type: Article

References (56)

1. Meek P, McKeithan K, Schumock G. Economic considerations in Alzheimer's disease. Pharmacotherapy 1998;18:68-73.
2. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Unrealized prevention opportunities: Reducing the health and economic burden of chronic illness, November 2000.
3. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood) 1993;12:164-176.
4. Max W, Webber P, Fox P. Alzheimer's disease: the unpaid burden of caring. J Aging Health 1995;7:179-199.
5. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease: an exploratory study. Arch Neurol 1997;54:687-693.
6. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998;159:457-465.
7. Leon J, Cheng CK, Neumann PJ. Alzheimer's disease care: costs and potential savings. Health Aff (Millwood) 1998;17:206-216.
8. Souetre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom: cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. Br J Psychiatry 1999;174:51-55.
9. Taylor DH Jr, Sloan FA. How much do persons with Alzheimer's disease cost Medicare? J Am Geriatr Soc 2000;48:639-646.
10. Moore MJ, Zhu CW, Clipp EC. Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. J Gerontol B Psychol Sci Soc Sci 2001;56:S219-S228.
11. Small GW, McDonnell DD, Brooks RL, Papadopoulos G. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 2002;50:321-327.
12. Zhu C, Moore M, Clipp E. Dementia problem behavior and the production of informal caregiving services. J Econ Household 2003;1:59-76.
13. Gutterman EM, Markowitz JS, Lewis B, Fillit H. Cost of Alzheimer's disease and related dementia in managed-Medicare. J Am Geriatrics Soc 1999;47:1065-1071.
14. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 2000;6:S1139-S1144.
15. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17:403-408.
16. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002;59:1721-1729.
17. Murman DL, Colenda CC. The economic impact of neuropsychiatric symptoms in Alzheimer's disease: can drugs ease the burden? Pharmacoeconomics 2005;23:227-242.
18. Murman DL, Kuo SB, Powell MC, Colenda CC. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003;61:944-949.
19. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002;181:36-42.
20. Andersen CK, Lauridsen J, Andersen K, Kragh-Sorensen P. Cost of dementia: impact of disease progression estimated in longitudinal data. Scand J Public Health 2003;31:119-125.
21. Zhu C, Scarmeas N, Torgan R, et al. Clinical features associated with costs in early AD: baseline data from the predictors study. Neurology 2006;66:1021-1028.
22. Stern Y, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"): I. Study design, cohort description, and intersite comparisons. Alzheimer Dis Assoc Disord 1993;7:3-21.
23. Richards M, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease (the "predictors study"): II. Neurological, psychiatric, and demographic influences on baseline measures of disease severity Alzheimer Dis Assoc Disord 1993;7:22-32.
24. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004;63:975-982.
25. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Stern Y, Sano M, Paulson J, Mayeux R. Modified Mini-Mental State Examination: validity and reliability. Neurology 1987;37:179.
27. Agency for Healthcare Research and Quality. HCUPnet, Healthcare Cost and Utilization Project [online]. Available at: http://www.ahrq.gov/HCUPnet/. Accessed March 1, 2005.
28. Centers for Medicare and Medicaid Services. Clinical Diagnostic Laboratory Fee Schedule [online]. Available at: http://www.cms.hhs.gov/ providers/pufdownload/. Accessed March 1, 2005.
29. Centers for Medicare and Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) [online]. Available at: http://www.cms.hhs.gov/providers/ pufdownload/anhcpcdl.asp. Accessed March 1, 2005.
30. Drug topics red book. Montvale, NJ: Medical Economics Company/Thompson Medical Economics, 2000.
31. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
32. Devanand DP, Miller L, Richards M, et al. The Columbia University Scale for Psychopathology in Alzheimer's Disease. Arch Neurol 1992;49:371-376.
33. Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002;58:1182-1188.
34. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005;62:1601-1608.
35. Stern MB, Hurting HI. The clinical characteristics of Parkinson's disease and parkinsonian syndromes: diagnosis and assessment. In: The comprehensive management of Parkinson's disease. New York: PMA Corp, 1978:3-50.
36. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-1149.
37. Scarmeas N, Albert M, Brandt J, et al. Motor signs predict poor outcomes in Alzheimer disease. Neurology 2005;64:1696-1703.
38. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
39. Menzin J, Lang K, Friedman M, Neumann P, Cummings JL. The economic cost of Alzheimer's disease and related dementias to the California Medicaid program ("Medi-Cal") in 1995. Am J Geriatr Psychiatry 1999;7:300-308.
40. Council of Economic Advisers. Economic report of the President. Washington, DC, 2003.
41. Baltagi B. Analysis of panel data. New York: Wiley and Sons, 1995.
42. Singer J, Willet J. Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press, 2003.
43. Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Economic Rev 1981;71:801.
44. Stata [software program]. Version 9. College Station, TX.
45. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
46. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 2003;43:158-164.
47. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-263.
48. Albert SM, Glied S, Andrews H, Stern Y, Mayeux R. Primary care expenditures before the onset of Alzheimer's disease. Neurology 2002;59:573-578.
49. Katz SJ, Kabeto M, Langa KM. Gender disparities in the receipt of home care for elderly people with disability in the United States. JAMA 2000;284:3022-3027.
50. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 2003;138:273-287.
51. Harrow BS, Mahoney DF, Mendelsohn AB, et al. Variation in cost of informal caregiving and formal-service use for people with Alzheimer's disease. Am J Alzheimers Dis Other Demen 2004;19:299-308.
52. Hogan C, Lunney J, Gabel J, Lynn J. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood) 2001;20:188-195.
53. Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002;37:1625-1642.
54. Bianchetti A, Frisoni G, Ghisla K, Trabucchi M. Clinical predictors of the indirect costs of Alzheimer's disease. Arch Neurol 1998;55:130-131.
55. Leon J, Neumann PJ. The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999;5:867-877.
56. Corder LS, Woodbury MA, Manton KG. Proxy response patterns among the aged: effects on estimates of health status and medical care utilization from the 1982-1984 long-term care surveys. J Clin Epidemiol 1996;49:173-182.